--- a
+++ b/clusters/3009knumclusters/clust_298.txt
@@ -0,0 +1,365 @@
+Clinically significant ascites, defined as ascites that is symptomatic or has resulted in a paracentesis in the past 3 months
+Ascites or pleural effusion requiring intervention or that required intervention or recurred within three months prior to randomization
+Pericardial effusion (except trace effusion identified by echocardiogram) within three months prior to randomization
+No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Grade 3 or 4 thromboembolic event =< 6 months\r\n* Pericardial effusion =< 12 months (any grade)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 months
+Patients with malignant pleural effusions that do not resolve after first-line systemic therapy. Patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line systemic therapy.
+Patients must not have active pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray and echocardiogram within 28 days prior to registration; exception: if the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion =< grade 2 or pleural effusion =< grade 1
+Patient has pleural effusion, ascites, or pericardial fluid requiring drainage Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligible
+Have symptomatic ascites or pleural effusion.
+Has extensive pleural effusion which occupies greater than 50% of the total lung volume observed on screening imaging
+Symptomatic ascites or pleural effusion.
+Uncontrolled pleural effusion, pericardial effusion, or ascites
+Evidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome
+Symptomatic ascites or pleural effusion
+Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Participants (all indications) with confirmed bilateral pleural effusion and NSCLC participants with confirmed uni- or bilateral pleural effusion by X-ray are not eligible
+Refractory encephalopathy or ascites
+Has ascites or pleural effusion by physical exam
+Uncontrolled symptomatic ascites or pleural effusions within 6 months.
+Patients with significant visceral fluid collections including ascites, pericardial effusions, pleural effusions or others may experience delayed clearance of methotrexate and inability tolerate the proposed study treatment; while these are not absolute exclusions the Study Chair or co-Chairs should be contacted to discuss possible enrollment; patients with significant ascites defined as European Association for the Study of the Liver >= grade 2, or with asymptomatic pleural effusions with an estimated size > 200 mL, or with symptomatic pleural effusion of any size will be excluded
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior cycle 1, day 1
+Patients with active extra-abdominal disease including active malignant pleural effusion; patients who have been successfully treated with neoadjuvant chemotherapy and no longer have (malignant) pleural effusions may be included
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
+Fluctuating ascites
+Has symptomatic ascites or pleural effusion.
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
+No clinically significant pleural effusion
+Clinical evidence of ascites (trace ascites on imaging acceptable)
+Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis (i.e. ascites from cirrhosis requiring diuretics or paracentesis)
+No evidence of clinically apparent ascites or active encephalopathy, and/or varices that have not been treated; subjects with controlled ascites or encephalopathy are eligible so long as they meet Childs-Pugh score criterion; please note that controlled ascites and encephalopathy require scores of 2 each when calculating the C-P score
+Participants with confirmed bilateral pleural effusion
+Presence of fluid collection (ascites, pleural, or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.
+Patients with non-malignant pleural effusion are eligible\r\n* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n** When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n** Exudative pleural effusions are excluded, regardless of cytology\r\n** Effusions that are minimal (i.e, not visible on chest x-ray) that are too small to safely tap are eligible
+Patients with clinically significant ascites or pleural effusions.
+Relapsed or refractory, histologically confirmed follicular lymphoma, grade I, II, or IIIa which requires therapy defined by at least one of the following:\r\n* Constitutional symptoms \r\n* Cytopenias\r\n* High tumor burden (single mass > 7 cm, three masses > 3 cm, symptomatic splenomegaly, organ compression or compromise, ascites, pleural effusion)
+Pleural or pericardial effusions of any grade at study entry; subjects previously diagnosed with pleural/pericardial effusion of any grade resolved at the time of study entry are allowed
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
+Clinical ascites or metastatic pleural fluid
+Ascites refractory to medical therapy (mild to moderate ascites is allowed)
+Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
+No clinical evident ascites that required therapeutic paracentesis
+Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+For NSCLC, patients with clinical stage IIB-IV patients (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) are eligible, and for SCLC, limited-stage patients are eligible, if documented to be a candidate for definitive radiation and concurrent chemotherapy in the radiation oncologist or medical oncologist clinic note\r\n* Stage IV NSCLC patients are eligible only if they have a solitary brain metastasis\r\n* Patients with non-malignant pleural effusion are eligible,\r\n** If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n*** When pleural fluid is visible on both the computed tomography (CT) scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n*** Exudative pleural effusions are excluded, regardless of cytology\r\n*** Effusions that are minimal (i.e., not visible on chest x-ray) that are too small to safely tap are eligible
+Greater than minimal, exudative, or cytologically positive pleural effusions
+Evidence of measurable disease (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) outside of the peritoneal cavity (ex: mediastinal lymphadenopathy, parenchymal liver metastasis, or symptomatic pleural effusion proven or suspected to be due to cancer)\r\n* Note: Asymptomatic pleural effusion with or without minimal pleural involvement as long as there is no measurable disease outside the peritoneum/retroperitoneum is allowed
+Participants with bilateral pleural effusion and NSCLC participants with uni- or bilateral effusion confirmed at screening by X-ray are not eligible
+Pleural or pericardial effusion\r\n* A patient with pleural effusion may be enrolled the effusion is sampled by thoracentesis and cytology is negative or the effusion is seen on axial imaging but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance
+Pleural or pericardial effusion\r\n *Pleural effusions allowed if one of the following conditions are met: 1) negative cytology after adequate sampling by thoracentesis 2) effusion seen on CT scan but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance
+Part B3 only: Participants must have malignant pleural or peritoneal mesothelioma
+Patients with pleural effusion or abdominal/peritoneal ascites, except the finding of physiological levels of fluid.
+Concurrent medical condition that would increase drug toxicity: pleural or pericardial effusion, coagulation or platelet function disorder, ongoing or recent (less than 3 months gastrointestinal bleeding)
+Presence of medically significant third space fluid (symptomatic pericardial effusion, ascites or pleural effusion requiring repetitive paracentesis)
+Pleural effusion as the only evidence of metastatic disease
+Presence of a significant pleural effusion by chest x-ray
+Current, or history of a pericardial effusion, and/or hemodynamic compromise due to pericardial effusion of any size; minimal pericardial effusion < 50 cc is not excluded
+Uncontrolled tumor-related pain; pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; or, hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) (patients with indwelling catheters such as PleurX® are allowed)
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
+The presence of lung, liver, or known brain metastases, malignant pleural effusions, or malignant ascites
+A pleural effusion of moderate severity or worse.
+Symptomatic ascites or pleural effusion.
+Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks prior to registration
+Has clinically relevant ascites at baseline (defined as requiring paracentesis) or with moderate radiographic ascites; a minimal amount of radiographic ascites is allowed
+Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia.
+Grade 2 or higher ascites, pleural, or pericardial effusion within 4 weeks of study enrollment or any history of recurrent grade 2 or higher effusions requiring ongoing drainage.
+No clinically significant pleural effusion
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 21 days prior to registration
+Participants with uncontrolled gross ascites or encephalopathy; assessment of ascites will be determined by the treating physician
+Symptomatic pleural effusions or ascites (requiring constant or intermittent drainage)
+Clinically significant and/or rapidly accumulating ascites, pericardial and/or pleural effusions; mild ascites that does not preclude safe tumor biopsy as protocol specified is allowed at the discretion of the treating physician
+Patients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollment
+Ascites or pericardial effusion that required intervention within 3 months prior to study treatment
+Pleural effusions or ascites.
+Uncontrolled pleural or pericardial effusion or ascites that would require recurrent drainage
+Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia.
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\r\n* Subjects with indwelling drainage catheters are allowed
+Pleural effusion: when pleural fluid is visible on both CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; patients with effusions that are minimal (i.e. not visible on chest x-ray) or that are too small to safely tap are eligible
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+A pleural effusion of moderate severity or worse.
+High volume peritoneal or pleural effusions requiring a tap more frequently than every 14 days; moderate to severe ascites
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+No clinically significant pleural effusion
+Clinical ascites
+Patients with malignant small bowel obstruction within the last 6 months, on parenteral nutrition, clinically significant ascites (palpable on physical exam and/or causing symptoms) or ascites requiring fluid removal more than twice in the last 6 weeks
+Patients must have a histologic diagnosis of malignant pleural mesothelioma
+Marked pleural effusion or ascites above Grade 2, based on NCI-CTCAE v4.03 criteria
+No pleural or peritoneal serous effusion.
+DASATINIB\r\n* Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)\r\n* Known pulmonary arterial hypertension\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretion
+No pleural or pericardial effusion of any grade
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to initiation of ABC294640
+Ascites requiring active medical management including paracentesis
+The patient does not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
+Moderate to large volume ascites.
+Presence of third space fluid which cannot be controlled by drainage; for patients who develop or have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before or during initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing; however, if, in the investigator's opinion, the effusion represents progression of disease, the patient should be discontinued from study therapy
+Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to lymphoma
+Uncontrolled effusion e.g., presence of third space fluid that, in the opinion of the investigator, cannot be successfully controlled by drainage\r\n* Note: Patients with small effusions remaining after pleurodesis are eligible; determination of eligibility based on pleural size will be determined by the principal investigator
+Significant ascites that require therapeutic paracentesis
+REGORAFENIB EXCLUSION CRITERIA: Pleural effusion or ascites causing respiratory compromise (dyspnea grade 2 or higher)
+Presence of ascites (as determined by clinician)
+Presence of pleural effusion
+The patient does not have: \r\n* Cirrhosis at a level of Child-Pugh B (or worse) or\r\n* Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
+History of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trial
+Any clinical or radiological ascites or pleural effusions
+Pleural effusion or ascites that causes respiratory compromise (? NCI-CTCAE version 4.03 Grade 2 dyspnea)
+Patients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligible
+Patients with evidence of a malignant pleural or pericardial effusion
+Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
+Pleural effusion or ascites that causes respiratory compromise (ie, >= grade 2 dyspnea)
+Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis unless due to lymphoma
+Uncontrolled pleural or pericardial effusion or ascites that would require recurrent drainage
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
+If a pleural effusion is present and visible on both CT scan AND chest x-ray, the investigator should exclude malignant disease by pleurocentesis to confirm cytologically-negative pleural fluid; if fluid is exudative or cytologically positive for tumor cells, patient is excluded\r\n* Patients with effusions that are minimal (i.e. not visible on chest x-ray) and that are too small to safely tap are eligible
+If the patient has received pre-operative neoadjuvant chemotherapy, evidence of response must be documented by at least one of the following: decline in serum carcinoma antigen (CA)125 level, at least a 30% decrease in the sum of the longest diameter of target lesions on radiographic imaging, or resolution of ascites or pleural effusion(s)
+Symptomatic ascites or pleural effusion
+Ascites refractory to medical therapy
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
+Ascites refractory to medical therapy
+Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly)
+Pleural/pericardial effusion or ascites > 1 L
+Subjects with malignant pleural effusions and malignant ascites
+Patients with clinically significant pleural or pericardial effusions
+Any evidence of ascites (beyond trace)
+Dasatinib \r\n* Known pulmonary arterial hypertension\r\n* Patients may not have pleural or pericardial effusion of any grade\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretion\r\n* Uncontrolled hypertension: inability to maintain blood pressure below the limit of 140/90 mgHg\r\n* Any history of second or third degree heart block (may be eligible of the subject currently has a pacemaker)
+Patients with known, clinically significant pericardial or pleural effusion
+Subjects with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the Principal Investigator (PI)
+Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia
+Pleural effusion or ascites that causes > grade 1 dyspnea
+Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
+History of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy or pleural effusions related to liver insufficiency within 6 months of screening
+Presence of third space fluid that cannot be controlled by drainage\r\n* For patients who develop or have baseline clinically significant pleural effusions before or during initiation of pemetrexed therapy; consideration should be given to drain the effusion prior to chemotherapy administration
+Measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria or non-measurable disease with symptomatic malignant pleural effusion or malignant ascites; if only site of disease is a pleural effusion, cytologic confirmation of recurrence should be obtained
+Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
+Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
+Clinically significant pleural effusion that either required pleurocentesis or is associated with shortness of breath.
+Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures >/=1 time per month
+Evidence of significant ascites as determined by the investigator
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
+Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration are NOT eligible for participation
+Pleural effusion or ascites that causes respiratory compromise (? CTCAE Grade 2 dyspnea).
+Has symptomatic ascites or pleural effusion
+Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
+Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
+Normal lung function with no dyspnea at rest, pleural effusion or oxygen requirement
+Clinically significant pleural effusion
+Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart
+Has ascites that requires frequent paracentesis or a pleural effusion that requires repeated thoracentesis
+Pleural effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible
+Exudative pleural effusion, regardless of cytology
+Has significant ascites or pleural effusion requiring drainage for symptom relief
+Clinically detectable (by physical exam) third?space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Uncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
+Pleural effusion that cannot be controlled with appropriate interventions
+Pleural effusion or ascites that causes respiratory compromise (eg, >= grade 2 dyspnea)
+Ascites, pleural effusion or pericardial fluid requiring drainage in the last 4 weeks
+Ascites requiring active medical management, including paracentesis
+Pleural effusion requiring active medical management
+Ascites requiring active medical management including paracentesis.
+Cytologically positive pleural effusion
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
+Pleural effusion that cannot be controlled despite appropriate interventions
+Active signs and symptoms of interstitial lung disease pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)
+If a pleural effusion is present, the following criteria must be met at registration to exclude malignant involvement (incurable M1a disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) and that are too small to safely tap are eligible
+Subjects with pleural effusion requiring thoracentesis or ascites requiring paracentesis within 14 days prior to admission
+Patients with symptomatic effusions (pleural, pericardial, or peritoneal) and/or those who have required a procedure for symptomatic effusions within 4 weeks of start of dasatinib are ineligible
+Patients must be willing and able to undergo ascites fluid collection pre- and post-study treatment if adequate ascites is present; patients without adequate ascites may also participate in the trial
+Patients with pre-existing interstitial lung disease (ILD), or pericardial/pleural effusion of grade 2 or higher; trace pericardial or pleural effusion is acceptable
+The presence of liver, or known brain metastases, malignant pleural effusions, or malignant ascites
+Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
+Patients with evidence of a malignant pleural or pericardial effusion are excluded
+Exclusion at the discretion of the principal investigator (PI) or delegate if participation to the study is deemed too risky (e.g. clinically significant pleural or pericardial effusion or ascites with possibly increased radio-toxicity)
+Symptomatic ascites or pleural effusions
+If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (incurable M1a disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Exudative pleural effusions are excluded, regardless of cytology\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) that are too small to safely tap are eligible
+For Cohort B: Has ascites and/or clinically significant pleural effusion
+Patients having:\r\n* Cirrhosis at a level of Child-Pugh B (or worse) or\r\n* Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once monthly.
+Grade 3-4 ascites or pleural effusion\r\n* Note: The following will NOT be exclusionary: A participant who is clinically stable following treatment for ascites or pleural effusion (including therapeutic thoracentesis or paracentesis)
+Clinically evident ascites (trace ascites on imaging is acceptable)
+Malignant pleural effusion
+Significant ascites or pericardial or pleural effusion
+Has symptomatic ascites or pleural effusion.
+Have greater than grade 2 ascites at time of enrollment.
+Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites
+Patients with ascites requiring paracentesis within 2 weeks prior to study entry (signature of informed consent) and during the screening period.
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); participants with indwelling catheters are eligible
+Have presence of clinically relevant ascites.
+Subjects with ascites or pleural effusion requiring drainage within the last 28 days.
+Significant or symptomatic amount of ascites should be drained prior to first dose of BBI608.
+Symptomatic ascites or pleural effusion
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Ascites requiring active medical management including paracentesis.
+Patients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; if a pleural effusion can be seen on the chest computed tomography (CT) but is too small to tap, the patient is eligible
+Clinically evident ascites (trace ascites on imaging is acceptable)
+Pleural mesothelioma basket:\r\n* None
+Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage procedures
+Presence of a small (or greater size) pericardial effusion
+Pleural effusion or ascites that causes respiratory compromise (? NCI-CTCAE version 4.03 Grade 2 dyspnea).
+cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
+No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Pericardial effusion =< 12 months (grade 3 or 4)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 months
+Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches; an indwelling drainage device placed prior to enrollment is acceptable
+Diagnosis of histologically or cytologically documented, malignant pleural effusions (primary non-small cell lung carcinoma, mesothelioma, and other histologies), who have free pleural space (partial or total) that permits the intrapleural drug instillation; this includes cytologically negative pleural effusion in conjunction with histologically proven malignancy involving the pleura
+Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.
+Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).
+If pleural fluid is visible on CT scan thoracentesis to exclude malignancy should be obtained. Patients with effusions that are too small to tap are eligible.
+Greater than minimal, exudative, or cytologically positive pleural effusions
+Uncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage catheters allowed)
+Symptomatic ascites or pleural effusion
+No clinical ascites (mild ascites on scans permissible)
+Ascites requiring intervention
+History of ascites or pleural effusions, unless successfully treated.
+Symptomatic effusions due to pleural, pericardial, or peritoneal metastasis of epithelial ovarian cancer
+Subject has uncontrolled symptomatic ascites.
+Patients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligible
+Pleural effusions requiring thoracentesis, or ascites requiring paracentesis, within 14 days prior to enrollment
+Uncontrolled or clinically relevant ascites
+Histologically confirmed metastatic ovarian or GI malignancy with malignant ascites amenable for paracentesis; adjudication of malignant ascites can be made on clinical grounds e.g. in the absence of cirrhosis or other non-malignant causes of ascites
+Pleural effusions requiring thoracentesis within the 14 days prior to randomization
+Ascites requiring paracentesis within the 14 days prior to randomization
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Pleural effusion or ascites that causes respiratory compromise (>= CTCAE version 4.0 grade 2 dyspnea)
+Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis
+Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
+Have clinically significant and/or malignant pleural effusion (pleural effusions that are not clinically significant are allowed, defined as no more than 25% fluid level of the corresponding hemithorax and stable fluid level [non-progressive] over at least 6 weeks documented radiographically)
+The presence of known brain metastases, malignant pleural effusions, or malignant ascites; brain MRI is required at screening only if clinically indicated
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
+No clinically significant evidence of pleural effusion or ascites
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to the first day of treatment
+No subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to cycle 1 day 1
+Uncontrolled tumor-related pain or uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent (once monthly or more frequently) drainage procedures
+Documented extensive disease, defined as any tumor beyond the above limited disease definition, including ipsilateral lung metastases and malignant pleural effusion.
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
+No moderate-to-severe ascites (subjects with ascites restricted to the perihepatic space or pelvic cavity)
+Clinical ascites
+Clinically evident ascites (trace ascites on imaging is acceptable)
+Patients with clinically significant pleural or pericardial effusions
+Patients with symptomatic effusions on account of pleural, pericardial or peritoneal metastases of melanoma
+Known presence of central nervous system metastases, pleural effusions or ascites
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
+Presence of symptomatic pleural and/or pericardial effusion not appropriately treated
+Ascites detected by CT, ultrasound (US) or MRI; (trace ascites will not be an exclusion)
+Presence of symptomatic pleural and/or pericardial effusion not appropriated treated
+Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to pre-existing pulmonary or cardiac impairment including pleural effusion requiring thoracentesis to ascites requiring paracentesis
+Patients with a history of malignant pleural effusions are not eligible; pleural effusions considered by the investigator too small for a diagnostic thoracentesis are permissible
+Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)
+Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
+Have clinically significant and/or malignant pleural effusion
+Patients with a pleural effusion requiring continuous drainage
+Pleural effusion large enough to be detectable on chest x-ray
+Patients cannot have active ascites
+Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
+Subjects with refractory ascites, defined as ascites needing drainage catheter or therapeutic paracentesis more often than every 4 weeks
+Patients with a pleural effusion which is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are not eligible; if a pleural effusion can be seen on the chest CT but not on CXR and is too small to tap, the patient will be eligible
+For metastatic solid tumors with documented malignant pleural and/or peritoneal effusions, patients must not be receiving specific therapy for the effusion or have an indwelling drain.
+Concurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any grade
+Patients with any pulmonary infiltrate including those suspected to be of infectious origin. Exception: Patients with a pleural effusion related to the disease under study as confirmed by the investigator are permitted to enter the study
+Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia
+Has symptomatic ascites or pleural effusion
+Pleural effusion or ascites that causes respiratory compromise (? NCI CTCAE version 4.0 Grade 2 dyspnea).
+Subject's with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the principal investigator (PI)
+Symptomatic pleural effusion (> CTCAE Grade 1 dyspnea) that is not amenable to drainage
+Recurrent symptomatic malignant ascites having required at least 2 paracenteses within a 45-day interval prior to baseline paracentesis
+Compensated cirrhosis defined as a Child-Pugh score of 5 or 6 at Screening • A minimal rim of ascites if detected at imaging is acceptable. Exclude ascites that requires the need to apply diuretic treatment to control ascites
+Pleural effusion or ascites > 1 liter
+Significant or symptomatic amounts of ascites should be drained prior to Cycle 1 Day
+Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea); patients may undergo thoracentesis and paracentesis to improve symptoms prior to enrollment
+Malignant pleural, pericardial, or peritoneal effusion if it is the only site of disease activity; i.e., if no other measurable tumor lesions exist
+Clinically significant (in the opinion of the Investigator) ascites or pleural effusion requiring chronic medical intervention
+Patients with clinically evident ascites requiring medical management or paracentesis, or Childs-Pugh score B/C are not eligible
+Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis to ascites requiring paracentesis
+Prior history of pericarditis or pericardial effusion
+Patients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy
+If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible
+Clinically significant third-space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
+Patients with malignant pleural effusions or significant pericardial effusions
+Patients with symptomatic effusions on account of pleural, pericardial or peritoneal metastases of melanoma
+Stage IV cancer according to TNM classification (7th edition - UICC, December 2009; includes tumor with malignant pleural or pericardial effusion
+Pleural effusion large enough to be detectable on chest x-ray (CXR)
+Patients require regular ascites/pleural effusion drainage
+Free flowing pleural effusion requiring management by placement of a pleural catheter; patients with a functional pleural catheter already in place are eligible for the study, as long as there are no clinical concerns of infection
+No free-flowing pleural effusion
+Cardiac ejection fraction >50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant pleural effusion
+Clinically significant pleural effusion.
+Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
+Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
+Uncontrolled pleural effusion, pericardial effusion, or ascites
+Clinically significant pleural effusion
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
+Patient with pleural effusion, ascites, or pericardial fluid requiring drainage.
+Patient has pleural effusion, ascites, or pericardial fluid requiring drainage. Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligible.
+Presence of tumor metastases causing significant pleural disease/effusion unilaterally or bilaterally (significant pleural effusion is defined by need for thoracentesis more frequently than once every 21 days)
+Presence of ascites that requires paracentesis more frequently than once every 21 days.
+Malignant pleural effusion or pleural disease
+Pleural effusion requiring repetitive drainage, i.e., an indwelling catheter or 2 thoracenteses with 6 weeks of the first dose of mogamulizumab;
+Malignant pleural effusion that is recurrent
+Clinically evident ascites
+History of recurrent ascites requiring paracentesis within 4 weeks of study day 1.
+Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
+Clinically significant and/or malignant pleural effusion
+Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days of first dose
+Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequently
+History of medically significant ascites requiring repetitive paracentesis
+Pleural effusion or ascites that causes respiratory compromise
+Any cause of dyspnea that is determined by the investigators as readily reversible by other means (e.g. pleural effusion, pulmonary embolism, acute infection, anemia hemoglobin [Hb] < 9.0, etc.)
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
+Pleural effusion or clinically evident (visible or palpable) ascites
+Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)
+Uncontrolled clinical symptoms including pleural effusion, pericardial effusion, or ascites, tumor-related pain, hypercalcemia (or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy)
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
+Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.
+Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
+Have clinically significant and/or malignant pleural effusion
+The participant has clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
+Pleural effusions requiring thoracentesis or ascites requiring paracentesis
+Pleural effusions requiring thoracentesis or ascites requiring paracentesis
+Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
+Ascites, pleural effusions, or osteoblastic bone metastases as the only site of disease.
+Pre-existing ascites (abdominal fluid collection) and/or clinically significant pleural effusion ( fluid collection between the lung and chest wall)
+Presence of large accumulation of ascites or pleural effusions, which would be a contraindication to the administration of methotrexate for GVHD prophylaxis
+Evidence of ascites on imaging study, or the use of diuretics for ascites
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
+No effusion or ascites > 1 L prior to drainage
+Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea CTCAE)
+Must meet criteria for initiation of treatment, consisting of:\r\n* Aggressive histology, or \r\n* Indolent histology with one of the following markers of large tumor burden:\r\n** Any nodal or extranodal tumor mass >= 7 cm in greatest dimension\r\n** >= 3 nodal masses that are each >= 3 cm in greatest dimension\r\n** Systemic symptoms\r\n** Cytopenias (leukocytes < 1 x 10^9/L and/or platelets, 100 x 10^9/L)\r\n** Substantial splenomegaly\r\n** Serous effusion (pleural effusion or peritoneal ascites)\r\n** Orbital or epidural involvement\r\n** Ureteral compression\r\n** Leukemic phase (malignant cells >= 5 x 10^9/L)
+Uncontrolled pleural effusion or ascites
+Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
+Ascites requiring paracentesis for symptom improvement
+Pleural effusion requiring thoracentesis within 1 week of study enrollment or scheduled during the study period
+Subject has a symptomatic malignant pleural effusion requiring intervention; for an effusion to be defined as malignant, at least one of the following must be true\r\n* There is cytological confirmation of pleural malignancy\r\n* The effusion is an exudate (per Light’s criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified
+Subject has sufficient pleural fluid to allow safe insertion of an indwelling tunneled pleural catheter as determined by the principal investigator (PI)
+Subject is able to perform home drainage of the pleural effusion or has sufficient resources (family member, caregiver, home health)
+All patients whom do not have malignant pleural effusions
+Patients presenting with ascites
+Patients with minimal pleural effusion evident on chest X-ray (CXR); minimal pleural effusion visible on chest CT is allowed
+Presence of ascites
+Presence of a symptomatic moderate or large free-flowing pleural effusion on the basis of:\r\n* Chest radiograph: effusion filling >= 1/3 the hemithorax, OR\r\n* Computed tomography (CT)-scan: maximum anteroposterior (AP) depth of the effusion >= 1/3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung completely surrounded by effusion, OR\r\n* Ultrasound: effusion spanning at least three rib spaces with depth of 3 cm or greater in at least one interspace, while the patient sits upright
+Pleural effusion is smaller than expected on bedside pre-procedure ultrasound
+Signs of third spacing as determined by the treating physician (e.g., pedal edema, pleural effusion, ascites)
+More than 1 biopsy on the same side requiring more than 1 pleural puncture
+Uncontrolled pleural effusion, pericardial effusion, or ascites
+Subject has a history of at least 1 ipsilateral pleural effusion causing dyspnea that responded to thoracentesis where the lung expanded and the dyspnea was improved.
+Patients with symptomatic pleural effusion requiring placement of an indwelling pleural catheter (IPC) or new placement of an IPC.
+Positive effusion cytology
+Patients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are ineligible; if a pleural effusion can be seen on the chest computed tomography (CT) but not on chest x-ray (CXR) and is too small to tap, the patient will be eligible
+Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
+Ascites absent
+Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures
+Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
+Unmeasurable target tumor site by RECIST 1.1 or PRC (example [ex]: lesions < 2 cm on computed tomography [CT] or magnetic resonance [MR] scan, leptomeningeal disease, ascites, pleural/pericardial effusion, lymphangitis, non-fludeoxyglucose [FDG]-avid skin lesions)
+Malignant pleural effusion or pericardial effusion
+Uncontrolled large ascites
+Patients with non-measurable non-evaluable lesions such as pleural effusion are not eligible to participate
+No clinically significant pleural effusion
+Clinically or radiographically detectable ascites (beyond trace/rim of ascites) or ascites requiring medication
+Minimal or non-symptomatic ascites
+Has symptomatic ascites or pleural effusion
+Subjects with prior history of pericardial effusion or pleural effusion that required thoracentesis are excluded. Subjects with prior history of pericardial or pleural effusion that was clinically manageable and a maintained CMR for ? 1 year on a stable dose of dasatinib are allowed.
+Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
+Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
+Significant pericardial effusion, pleural effusion, or ascites